Related Experiment Video

Updated: Mar 22, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.1K

Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation

Francesco Paolo Fiorentino1, Elvan Tokgün1, Sònia Solé-Sánchez1

  • 1Genomics and Epigenomics of Cancer Prediction Program, Institute of Predictive and Personalized Medicine of Cancer (IMPPC), Campus Can Ruti, Barcelona, Spain.

Oncotarget
|April 23, 2016
PubMed

Insights

Omomyc effectively inhibited small cell lung cancer (SCLC) growth by inducing cell cycle arrest and apoptosis. Targeting MYC, a key protein in SCLC, presents a promising therapeutic strategy for patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Small cell lung cancer (SCLC) is highly aggressive with poor outcomes.
  • MYC gene family amplification occurs in approximately 20% of SCLC cases, making MYC proteins potential therapeutic targets.
  • MYC proteins play a crucial role in the proliferation of SCLC cells.

Purpose of the Study:

  • To investigate the therapeutic potential of Omomyc, a dominant-negative MYC inhibitor, in SCLC.
  • To determine the mechanisms by which Omomyc affects SCLC cell growth.
  • To assess the efficacy of targeting MYC in SCLC.

Main Methods:

  • Treatment of SCLC cell lines with Omomyc.
  • Assessment of cell growth, cell cycle arrest, and apoptosis.
  • Analysis of CDKN1A and TP73 pathway activation.

Main Results:

  • Omomyc suppressed the growth of all tested SCLC cell lines.
  • Omomyc treatment induced cell cycle arrest and/or apoptosis in SCLC cells.
  • G1 cell cycle arrest was dependent on CDKN1A activation, partly via the TP73 pathway.

Conclusions:

  • SCLC cells with MYC, MYCL, or MYCN amplification are dependent on MYC function.
  • Omomyc demonstrates significant therapeutic potential for SCLC patients with MYC pathway alterations.
  • Targeting MYC represents an effective therapeutic strategy for a subset of SCLC patients.
Keywords:
CDKN1AMYCMYCLSCLCsmall cell lung cancer

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

9.0K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K